MAP3K20

Across TCGA pan-cancer cohorts, MAP3K20 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated MAP3K20 data layer compared with 7 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher MAP3K20 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP3K20 expression acts as an unfavorable survival marker, although some lineages such as ESCA and PRAD show a favorable association.

UVM, MESO, and ACC are the cancer types where MAP3K20 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	DFS	Tertile	II,III,IV	0.276	0.830	<.001	120	view →
MESO	OS	Median	All	0.435	0.645	<.001	82	view →
ACC	DFS	Tertile	All	0.508	0.859	<.001	57	view →
KIRP	DFS	Tertile	All	0.769	0.923	.002	54	view →
LGG	OS	Median	All	0.694	0.926	<.001	54	view →
BLCA	OS	Quartile	All	0.505	0.744	<.001	53	view →
KICH	DFS	Tertile	II,III,IV	0.486	1.000	<.001	50	view →
ESCA	DFS	Tertile	III,IV	0.555	0.251	.005	24	view →
CESC	DFS	Quartile	All	0.721	0.868	.004	20	view →
CHOL	DFS	Tertile	III,IV	0.172	0.779	.024	18	view →
PRAD	DFS	Quartile	All	0.904	0.704	.010	16	view →
KIRC	DFS	Tertile	III,IV	0.777	0.574	.031	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

MAP3K20–UVM (DFS)

Open the UVM breakdown →